Semaglutide for PCOS: Evidence, Eligibility, Coverage

Semaglutide is not FDA approved for polycystic ovary syndrome (PCOS). It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Brands: Ozempic, Wegovy and Rybelsus
Best result (STEP 1): 14.9% weight loss

Wegovy, in short

How long it remains in your body

The half-life is about 1 week: by 7 d half is gone, and after five half-lives (35 d) about 3% is left.

Amount of weight lost in its main trial

In STEP 1 over 68 weeks, body weight fell 14.9%, compared with 2.4% on placebo.

Cost over time

Prices each month in US dollars cover the list price and self-pay offers, with values taken from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Semaglutide: who qualifies
Who sets the rule	Who qualifies
Ozempic	It lowers blood sugar in adults with type 2 diabetes when used with diet and exercise.
Ozempic	Adults who have heart disease and also type 2 diabetes see a lower risk of a heart attack, of a stroke, or of heart-related death with this medicine.
Ozempic	It reduces the risk that kidney disease gets worse, and lowers the risk of kidney failure and of heart-related death, among adults with chronic kidney disease and type 2 diabetes.
Wegovy	Adults with heart disease plus obesity or overweight see a lower risk of a heart attack or stroke, and of heart-related death (injection and tablets).
Wegovy	It supports weight loss and maintaining it long term when you pair it with diet and activity. This applies to adults and children 12 and older with obesity, and to adults who have overweight together with a weight-related condition.
Wegovy	For adults, it treats MASH liver disease when scarring is moderate to advanced and cirrhosis is not present.
Wegovy	For adults, these tablets are approved for weight loss and heart risk.
Rybelsus	It lowers blood sugar in adults with type 2 diabetes when used with diet and exercise.
Rybelsus	Adults with type 2 diabetes who are at high risk face a smaller chance of a heart attack, a stroke, or a heart-related death.
Medicare GLP-1 Bridge	BMI 35 or higher, no condition needed
Medicare GLP-1 Bridge	Uncontrolled blood pressure, CKD 3a+, or heart failure, together with BMI 30 or higher
Medicare GLP-1 Bridge	A previous heart attack or stroke, Prediabetes, or PAD, with BMI 27 or higher
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	you start with a diet and activity program for 6 months

Sources: 1 2 3 from the FDA label (DailyMed), plus medicare.gov 1 2, and aetna.com.

Trial results for PCOS

These trials did not enroll only people with polycystic ovary syndrome (PCOS). Everyone studied was an adult with obesity or overweight, without diabetes.

Semaglutide and polycystic ovary syndrome (PCOS) trials
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

Source for the trial: STEP 1 (FDA label (DailyMed)).

What is different for PCOS?

What the semaglutide label says about polycystic ovary syndrome (PCOS)
What changes	What the label says	Labels
Hypoglycemia When Combined With Insulin Secretagogues or Insulin	Using it with insulin or a sulfonylurea raises the chance of low blood sugar, and those doses may need lowering.	All of them

Source: the FDA labels, FDA label (DailyMed).

These label warnings come from: FDA label (DailyMed).

Coverage for PCOS

GLP-1 medicines prescribed for weight loss alone are not covered by Medicare Part D.

People who meet the rules can find Wegovy listed at $50 per month in the Medicare GLP-1 Bridge.

Where Medicaid covers weight-loss GLP-1s, prior authorization is normally required.

Sources: humana.com, CMS, KFF.

Alternatives for PCOS

GLP-1 medicines and polycystic ovary syndrome (PCOS)
Medicine	For PCOS	How it is taken	Trial result
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed